Also found in: Wikipedia.


(na-ta-li-zoo-mab) ,


(trade name)


Therapeutic: anti multiple sclerosis agents
Pharmacologic: monoclonal antibodies
Pregnancy Category: C


To reduce the frequency of exacerbations of relapsing multiple sclerosis.Inducing and maintaining remission in moderately to severely active Crohn's disease in patients who have been unresponsive to conventional therapies, including tumor-necrosis factor inhibitors.


Binds to integrin receptors on non-neutrophil leukocytes which may alter adhesion and migration characteristics involved in the crossing of activated inflammatory cells into the CNS.

Therapeutic effects

Fewer exacerbations of relapsing multiple sclerosis.


Absorption: IV administration results in complete bioavailability.
Distribution: Unknown.
Metabolism and Excretion: Unknown.
Half-life: 7–15 days.

Time/action profile



Contraindicated in: Hypersensitivity; Concurrent use of immunosupressants or tumor-necrosis factor inhibitors; History of progressive multifocal leukoencephalopathy (PML); Pediatric: Children <18 yr.
Use Cautiously in: Anti-JC virus (JCV) positive Obstetric: Use only if clearly needed.

Adverse Reactions/Side Effects

Central nervous system

  • depression
  • fatigue


  • hepatotoxicity (life-threatening)
  • cholelithiasis


  • melanoma


  • allergic reactions including anaphylaxis
  • infections
  • PML (life-threatening)
  • infusion-related reactions


Drug-Drug interaction

↑ risk of infection with immunosupressants (avoid concurrent use).


NOTE: Because of the risk of PML, natalizumab is available only under a special restricted distribution program, the TOUCH Prescribing Program. Prescribers, pharmacies, and patients must be enrolled in the program to obtain the drug.

Multiple Sclerosis

Intravenous (Adults) 300 mg every 4 wk.

Crohn's Disease

Intravenous (Adults) 300 mg every 4 wk; if no response after 12 wk, or if patient cannot be tapered off corticosteroid therapy after 6 mo, discontinue therapy.


Solution for injection: 300 mg/15 mL

Nursing implications

Nursing assessment

  • Observe patient during infusion and for 1 hr after infusion is completed. Assess for signs of hypersensitivity reactions (urticaria, dizziness, fever, rash, rigors, pruritus, nausea, flushing, hypotension, dyspnea, chest pain, anaphylaxis), especially during first 2 hrs of infusion. If symptoms occur, discontinue natalizumab and treat symptoms.
  • Assess for new signs or symptoms suggestive of PML, an opportunistic infection of the brain caused by the JC virus, leading to death or severe disability; withhold dose and notify health care professional promptly. Monitor during therapy and for at least 6 months following discontinuation. PML symptoms may begin gradually but usually worsen rapidly. Symptoms vary depending on which part of the brain is infected (mental function declines rapidly and progressively, causing dementia; speaking becomes increasingly difficult; partial blindness; difficulty walking; rarely, headaches and seizures occur). Diagnosis is usually made via gadolinium-enhanced MRI and CSF analysis. Risk of PML increases with the number of infusions. Withhold natalizumab at first sign of PML.
  • Obtain an MRI of the brain prior to initiating therapy to help in differentiating symptoms of MS with those of PML.
  • MS: Assess frequency of exacerbations of symptoms of multiple sclerosis periodically during therapy.
  • Crohn's disease: Assess abdominal pain and frequency, quantity, and consistency of stools at beginning and during therapy.
  • Lab Test Considerations: May cause ↑ lymphocytes, monocytes, eosinophils, basophils, and nucleated RBCs. These ↑ persist during therapy but usually return to baseline within 16 weeks after last dose. Neutrophil ↑ do not usually occur.
    • May cause hepatotoxicity. Monitor for ↑ serum hepatic enzymes and total bilirubin may occur within 6 days after the first dose or for the first time after multiple doses. Discontinue if jaundice or other evidence of hepatotoxicity occurs.
    • Monitor serum JCV antibodies periodically during therapy. Patients with a negative antibody should be retested periodically during therapy due potential for false-positive results or a new infection.

Potential Nursing Diagnoses

Deficient knowledge, related to medication regimen (Patient/Family Teaching)


  • Intravenous Administration
  • Intermittent Infusion: Diluent: Dilute 300 mg in 100 mL of 0.9% NaCl. Invert to mix solution; do not shake. Do not mix with other diluents. Solution is colorless and clear to slightly opalescent. Do not administer solutions that are discolored or contain particulate matter. Administer immediately after dilution or refrigerate and use within 8 hrs. Concentration: 2.6 mg/mL.
  • Rate: Infuse over 1 hr. Do not use filtration devices. Do not administer as IV push or bolus injection.

Patient/Family Teaching

  • Inform patient of purpose of medication. Patients must visit their health care professional/prescriber 3 and 6 months after first infusion and every 6 months thereafter for follow-up exam.
  • Instruct patient to read the Medication Guide before starting the infusion. Natalizumab is available only through a special restricted distribution program called the TOUCH™ Prescribing Program, MS-TOUCH for multiple sclerosis and CD-TOUCH for Crohn's Disease, and must be administered only to patients enrolled in this program.
  • Instruct patient to report symptoms of PML (progressive weakness on one side of the body or clumsiness of limbs; disturbance of vision; changes in thinking, memory, and orientation leading to confusion and personality changes), hypersensitivity reactions, hepatotoxicity (yellowing of the skin and eyes, unusual darkening of the urine, nausea, feeling tired or weak, vomiting), or worsening of symptoms (new or sudden change in your thinking, eyesight, balance, or strength or other problems) that persist over several days to health care professional immediately.
  • Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
  • Instruct patient to inform all health care professionals about treatment with natalizumab.
  • Advise patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

  • Decrease in frequency of clinical exacerbations in patients with multiple sclerosis.
  • Decrease in signs and symptoms of Crohn's disease.
  • Patients must be evaluated at 3 mo and 6 mo after first infusion and every 6 mo thereafter to determine effectiveness.


a multiple sclerosis agent and monoclonal antibody.
indications This drug is used to treat ambulatory patients with relapsing-remitting multiple sclerosis who have not responded to other treatments. An unlabeled use is the treatment of Crohn's disease.
contraindications Progressive multifocal leukoencephalopathy; murine protein allergy; immunodeficiency (in patients with HIV, AIDS, leukemia, lymphoma, and transplants); and known hypersensitivity to this drug prohibit its use.
adverse effects Adverse effects of this drug include rigors, syncope, tremors, chest discomfort, hypertension, hypotension, abnormal liver function test, gastroenteritis, amenorrhea, vaginitis, urinary frequency, dermatitis, and pruritus. Life-threatening side effects include progressive multifocal leukoencephalopathy, suicidal ideation, anaphylaxis, and angioedema. Common side effects include headache, fatigue, depression, abdominal discomfort, urinary tract infection, irregular menses, rash, arthralgia, and lower respiratory tract infection.


A monoclonal antibody INTEGRIN (adhesion molecule) antagonist drug that has been used, apparently with success, to reduce the risk of progression of disablement in MULTIPLE SCLEROSIS. The drug interferes with the adhesion of lymphocytes to vascular endothelium in areas of inflammation.
References in periodicals archive ?
About 3,000 patients had received natalizumab in clinical trials, largely for MS.
The Food and Drug Administration's approval of natalizumab for the treatment of moderate to severe Crohn's disease in selected patients includes the requirement that the drug will be administered only through a restricted distribution program, the agency has announced.
Patients taking immunosuppressants while on natalizumab are at risk for "serious opportunistic and other atypical infections," including herpes, according to a press release from the FDA.
Natalizumab (Tysabri), which is currently under a new FDA review, is also injected.
Assessment of Baseline Treatment History and Postbaseline Relapses and Serious Adverse Events in MS Patients Treated with Natalizumab - S51.
ASCEND (A Study to Characterise the Efficacy of Natalizumab on Disability in SPMS) is a double-blind, placebo-controlled study with SPMS patients receiving either TYSABRI 300 mg or placebo intravenously every four weeks for a period of 96 weeks.
A federal advisory panel has recommended that the immune modulator natalizumab be approved to treat moderate to severe Crohn disease, but only under highly restrictive conditions.
Because of the serious risks associated with this agent, including progressive multifocal leukoencephalopathy (PML) and other opportunistic infections, the panel recommended that natalizumab use be restricted to those who have failed other treatments or cannot tolerate anti--tumor necrosis factor therapies.
Antegren is the trade name for natalizumab, an antibody that targets a protein on immune cells.
The Panel then turns to the more immediately commercially relevant question of comparing Simponi to other anti-TNF agents, next generation inhibitors of leukocyte trafficking to natalizumab and to each other, and both of these classes to p40 approaches.
Prior Information Notice without call for competition: Motol hospital - teriflunomide natalizumab, dimethyl - fumarate.
STRATIFY JCV was developed as part of an exclusive collaboration between Quest Diagnostics and Biogen Idec (NASDAQ:BIIB), which jointly develops natalizumab with Elan Corporation Plc (NYSE:ELN).